Ionis Pharmaceuticals (IONS) PT Raised to $64 at Needham & Company as ENDEAR Study Halted Early for Efficacy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- US stock futures tumble as Trump says Iran deal is 'over', oil climbs
- Oil jumps over 5% to two-week high after Trump says deal with Iran 'over'
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Amazon launches bond sale seeking at least $25 billion
- Raymond James Starts SpaceX (SPCX) at Strong Buy, PT Street High $800
Ionis Pharmaceuticals (IONS) PT Raised to $36 at Leerink Partners
August 1, 2016 3:30 PM EDTLeerink Partners analyst Michael Schmidt raised his price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $36.00 (from $26.00) after the company announced that nusinersen, its antisense drug in development for treatment of spinal muscular atrophy (SMA) met the primary endpoint at the interim analysis of the Ph III trial "ENDEAR", which is evaluating the drug's effect in infantile-onset Type I SMA.. The firm maintained an Market... More
Ionis Pharmaceuticals (IONS) PT Raised to $40 at BMO Capital
August 1, 2016 12:22 PM EDTBMO Capital analyst Do Kim raised his price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $40.00 (from $25.00) after positive interim data from the Phase III ENDEAR study for infant-onset SMA and Biogen exercising its option to license Nusinersen but maintained a Market Perform... More
Biogen (BIIB), Ionis (IONS) Announce Nusinersen Phase 3 Met Primary Endpoint in Infantile-Onset SMA
August 1, 2016 7:34 AM EDTBiogen (Nasdaq: BIIB) and Ionis Pharmaceuticals (Nasdaq: IONS) announced that nusinersen, their investigational treatment for spinal muscular atrophy (SMA), met the primary endpoint pre-specified for the interim analysis of ENDEAR, the Phase 3 trial evaluating nusinersen in infantile-onset (consistent with Type 1) SMA. The analysis found that infants receiving nusinersen experienced a statistically significant improvement in the achievement of motor milestones compared to those who did not receive treatment. Nusinersen demonstrated an acceptable safety profile in the trial. As a result of these findings, Biogen has exercised its option to develop... More
Ionis Pharma (IONS) Unit Receives EC Orphan Drug Designation Volanesorsen as FPL Treatment
July 28, 2016 4:01 PM EDTAkcea Therapeutics, a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today that the European Commission (EC) has designated volanesorsen as an orphan medicinal product for the treatment of familial partial lipodystrophy (FPL). FPL is a rare lipid disorder characterized by abnormal fat distribution across the body and a range of metabolic abnormalities, including severe type 2 diabetes, high triglycerides, and accumulation of fat in the... More
